AbbVie to buy immune drug developer Landos | BioPharma Dive
www.biopharmadive.com
biopharma divebuy
Pfizer resumes trial recruitment suspended by coronavirus...
www.biopharmadive.com
biopharma divetrial
Cytokinetics heart drug voted down by FDA panel | BioPharma Dive
www.biopharmadive.com
biopharma diveheart
Biotech and Pharma Industry News | BioPharma Dive
www.biopharmadive.com
pharma industrynews
FDA lifts pause on Novavax flu vaccine trials | BioPharma Dive
www.biopharmadive.com
flu vaccinefdalifts
Lilly stops trial of muscle-sparing obesity drug | BioPharma Dive
www.biopharmadive.com
biopharma divelilly
Abbott to acquire Exact Sciences for about $21B | BioPharma Dive
www.biopharmadive.com
exact sciencesdive
Calquence OK boosts AstraZeneca's challenge to Imbruvica...
www.biopharmadive.com
biopharma diveok
Medicines Co. gets cholesterol confirmation | BioPharma Dive
www.biopharmadive.com
biopharma diveco
Regeneron ups genetic medicine investment with Decibel buyout...
www.biopharmadive.com
biopharma diveups
FDA rejects Ultragenyx gene therapy over manufacturing concerns...
www.biopharmadive.com
gene therapyfdadive
FDA advisers push back on FibroGen anemia drug | BioPharma Dive
www.biopharmadive.com
push backfdaanemia
Alzheimer's disease | BioPharma Dive
www.biopharmadive.com
biopharma dive
AbbVie bets on early immuno-oncology asset | BioPharma Dive
www.biopharmadive.com
biopharma divebets
Hospitalized gene therapy patient triggers Sarepta sell off...
www.biopharmadive.com
gene therapypatient
AstraZeneca, Merck strengthen lead in PARP drug class...
www.biopharmadive.com
biopharma divemerck
ICER draws new gene therapy pricing framework | BioPharma Dive
www.biopharmadive.com
gene therapydraws
Emerging biotech | BioPharma Dive
www.biopharmadive.com
biopharma dive
Merck antibody drug for RSV approved by FDA | BioPharma Dive
www.biopharmadive.com
biopharma divemerck
Evommune nabs $150M in IPO amid federal shutdown | BioPharma Dive
www.biopharmadive.com
federal shutdownipo